CN116948028A - 一种抗抑制素抗体及其应用 - Google Patents
一种抗抑制素抗体及其应用 Download PDFInfo
- Publication number
- CN116948028A CN116948028A CN202311211224.2A CN202311211224A CN116948028A CN 116948028 A CN116948028 A CN 116948028A CN 202311211224 A CN202311211224 A CN 202311211224A CN 116948028 A CN116948028 A CN 116948028A
- Authority
- CN
- China
- Prior art keywords
- antibody
- inhibin
- statin
- fluorescently labeled
- increasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000893 inhibin Substances 0.000 title claims abstract description 59
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 230000016087 ovulation Effects 0.000 claims abstract description 15
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000008217 follicular development Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- -1 rhodomine B Chemical compound 0.000 claims 1
- 108010004250 Inhibins Proteins 0.000 abstract description 14
- 244000144972 livestock Species 0.000 abstract description 10
- 101001076604 Homo sapiens Inhibin alpha chain Proteins 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000012173 estrus Effects 0.000 abstract description 4
- 230000002163 immunogen Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000001360 synchronised effect Effects 0.000 abstract description 2
- 238000002054 transplantation Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 22
- 239000007928 intraperitoneal injection Substances 0.000 description 13
- 102000002746 Inhibins Human genes 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种抗抑制素抗体及其应用，其是以重组人抑制素α链为免疫原制备得到抗抑制素抗体，该抗体可以有效促进哺乳动物排卵，提高雌性哺乳动物的受孕率和产仔量。可用于开发促进动物繁殖、同期发情、受胎产仔、胚胎移植、提高排卵质量、促进家畜繁殖、诱导母畜发情的药物。同时，本发明的抗抑制素抗体对抑制素具有较高的亲和力，可应用于抑制素的检测分析，具有较高的灵敏性和检测下线。
Description
技术领域
本发明涉及抗抑制素抗体技术领域，更具体地，涉及一种抗抑制素抗体及其应用。
背景技术
抑制素是糖蛋白激素，由α与β亚单位经过两个硫键相连组成。于1932年，McCullagh在睾丸提取物中发现。抑制素源于睾丸支柱细胞的一种大分子多肽，具有强烈的抑制FSH分泌的作用，但对LH的分泌仅具轻微的抑制作用。抑制素由卵巢颗粒细胞分泌，相对分子质量为32000。抑制素可以反馈抑制垂体前叶促卵泡激素的释放，调节卵泡的生成。
目前，大量研究发现通过主动或被动免疫中和抑制素，促使内源FSH的产生和分泌，均能刺激雌性动物卵泡发育以及增加排卵数，表明这种两种方法都具有调控家畜繁殖性能的潜力，对畜牧生产和经济动物繁殖具有重要价值。
提高家畜产仔数的方法通常是对家畜注射FSH或FSH类似的药物，拮抗抑制素发挥作用，但是该方法却存在胚胎利用率低的问题。因此，如何有效提高家畜的繁殖能力对于当下家畜市场而言至关重要。
发明内容
针对现有技术所存在的技术问题，本发明提供了一种抗抑制素抗体及其应用。本研究以重组人抑制素α链为免疫原，并制备得到抗抑制素抗体，并发现该抗体可以有效促进哺乳动物排卵，提高雌性哺乳动物的受孕率和产仔量。
具体而言，本发明首先是提供了一种抗抑制素抗体，其特征在于，所述抗抑制素抗体重链可变区序列如SEQ ID NO.1所示，轻链可变区序列如SEQ ID NO.2所示。
进一步地，所述抗抑制素抗体重链可变区包括CDR1、CDR2和CDR3，其序列分别对应于SEQ ID NO.3-5所示，所述抗抑制素抗体轻链可变区包括CDR4、CDR5和CDR6，其序列分别对应于SEQ ID NO.6-8；
进一步地，本发明还提供了一种荧光标记的抗抑制素抗体，进一步地，本发明提供的所述荧光标记为FITC、FAM、Rhodamine B、TAMRA、Cy3、Cy5等荧光基团标记。
进一步地，本发明提供的所述荧光标记为FITC。
进一步地，本发明还提供了一种非诊断目的抑制素直接免疫荧光检测方法，该方法包括采用所述荧光标记的抗抑制素抗体接触待检样本，孵育结束后，在荧光显微镜下观察结果或酶标仪读取荧光值。
进一步地，本发明还提供了上述荧光标记的单克隆抗体在制备检测抑制素检测试剂盒中的应用。
进一步地，本发明还提供了抗抑制素抗体在制备用于刺激雌性哺乳动物卵泡发育、增加排卵数、增加受孕率或提高产仔量药物中的用途。
进一步地，所述雌性哺乳动物是选择鼠、猪、牛、羊等。
进一步地，本发明还提供了一种刺激雌性哺乳动物卵泡发育、增加排卵数、增加受孕率或提高产仔量的药物，其特征在于，所述药物包括所述的抗抑制素抗体和药学上可接受的辅料。
本发明的优点如下：本发明提供了以重组人抑制素α链为免疫原制备得到抗抑制素抗体，并发现该抗体可以有效促进哺乳动物排卵，提高雌性哺乳动物的受孕率和产仔量。可用于开发促进动物繁殖、同期发情、受胎产仔、胚胎移植、提高排卵质量、促进家畜繁殖、诱导母畜发情的药物。同时，本发明的抗抑制素抗体对抑制素具有较高的亲和力，可应用于抑制素的检测分析，具有较高的灵敏性和检测下线。
附图说明
图1为抗抑制素抗体对抑制素检测灵敏度分析。
具体实施方式
下面结合具体实施例对本发明作进一步的详细说明，以使本领域的技术人员更加清楚地理解本发明。
实施例1抗抑制素抗体的制备
1.1杂交瘤细胞系制备
以150μg/mL重组人抑制素α链（购自齐一生物科技（上海）有限公司）为免疫原对6只6-8周龄雌性BALB/c小鼠进行免疫注射，每次皮下注射150μL，间隔时间1周。经连续三次间隔免疫后，对小鼠断尾采血，用间接 ELISA 方法监测血清抗体效价，并选择效价最高的免疫小鼠，用纯的抗原液尾静脉加强免疫，3天后无菌采取小鼠脾细胞与 SP2/0 细胞融合，两种细胞之比为 1:10，将培养板放置 37℃ 5%的 CO2培养箱中培养。经6天的连续培养后，取上清进行抗体检测。
1.2杂交瘤细胞系筛选
用间接ELISA方法检测杂交瘤细胞分泌抗体的情况，以筛选出阳性细胞株。具体方法为取杂交瘤细胞培养上清150μL加入前日包被好的酶标板孔中，同时设立阳性、阴性对照和空白对照。判定标准为OD490值阳性孔与对照孔比值≥2.0判定为阳性。阴性孔3d后再检测一次，如仍为阴性则弃之。
1.3单克隆抗体免疫球蛋白重链和轻链类型的鉴定
取杂交瘤细胞株培养上清，采用IgG抗体检测试剂盒(上海抚生实业有限公司)测定抗体重链、轻链类型。
经鉴定，本发明所述抗抑制素抗体的重链可变区序列如SEQ ID NO.1所示，轻链可变区序列如SEQ ID NO.2所示。所述抗抑制素抗体重链可变区包括CDR1、CDR2和CDR3，其序列分别对应于SEQ ID NO.3-5所示，所述抗抑制素抗体轻链可变区包括CDR4、CDR5和CDR6，其序列分别对应于SEQ ID NO.6-8。
1.4单克隆抗体的特性鉴定
单抗效价的测定
用间接 ELISA 方法测定单克隆抗体的效价。以重组人抑制素α链为包被抗原，将抗抑制素抗体以 1:10 开始倍比稀释，同时以同等稀释度的注射 SP2/0 细胞的小鼠腹水作为阴性对照。以平行稀释的单抗 OD490值/对照OD490≥2.1 的最高稀释倍数为单抗的效价。结果显示：三免后小鼠的血清效价均在107以上，达到融合要求。
实施例2抗抑制素抗体对小鼠排卵影响
选取6-8周龄雌性小鼠，随机分成5组，每组5只小鼠，其中处理组1是腹腔注射1μg/kg抗抑制素抗体，处理组2是腹腔注射5μg/kg抗抑制素抗体，处理组3是腹腔注射10μg/kg抗抑制素抗体，阴性对照组是腹腔注射同等体积的生理盐水，阳性对照组是腹腔注射10IUPMSG。3天后进行二次腹腔注射，经二次注射后的第4天对参与实验小鼠进行解剖取卵计数。结果如表1所示。
表1. 抗抑制素抗体对小鼠排卵影响
| 阴性对照组 | 阳性对照组 | 处理组1 | 处理组2 | 处理组3 | |
| 排卵个数 | 0 | 17.6±1.23 | 21.8±1.62 | 26.2±2.51 | 32.7±2.85 |
从结果可以看出，腹腔注射本发明所述抗抑制素抗体后可以明显提高小鼠的排卵数量，且随着抗抑制素抗体的注射剂量的加大，小鼠排卵数量也呈现上升现象。
实施例3抗抑制素抗体对小鼠受胎率、产仔数的影响
选取6-8周龄雌性小鼠，随机分成5组，每组10只小鼠，其中处理组1是腹腔注射1μg/kg抗抑制素抗体，处理组2是腹腔注射5μg/kg抗抑制素抗体，处理组3是腹腔注射10μg/kg抗抑制素抗体，阴性对照组是腹腔注射同等体积的生理盐水，阳性对照组是腹腔注射10IUPMSG，腹腔注射后24h对每只小鼠注射10IU HCG并配种。25天后统计受胎率，产仔后统计产仔数。
结果如表2所示：在1μg/kg的抗抑制素抗体用量情况下，小鼠的受胎率(90％)明显高于阳性对照(60％)，其均产仔数平均可达到13.5只，且发现伴随着抗体剂量的增加，均产仔数也呈现上升趋势。同时可以看出，抗抑制素抗体在受胎率和均产仔数上均表现出色。
表2抗抑制素抗体对小鼠受胎率、产仔数的影响
| 组别 | 小鼠数量（只） | 受胎小鼠（只） | 受胎率（%） | 产仔数（只） | 均产仔数（只） |
| 阴性对照 | 10 | 3 | 30 | 22 | 7.3±0.89 |
| 阳性对照 | 10 | 6 | 60 | 59 | 9.8±0.96 |
| 处理组1 | 10 | 9 | 90 | 130 | 13.5±1.25 |
| 处理组2 | 10 | 10 | 100 | 145 | 14.5±1.05 |
| 处理组3 | 10 | 10 | 100 | 148 | 14.8±1.15 |
实施例4抗抑制素抗体对抑制素的检测分析
4.1荧光抗体的制备
取一定量的纯单抗溶液，在1.5 mol/L pH9.0碳酸盐缓冲液透析过夜，按荧光素与抗抑制素抗体质量比1:100称取适量FITC，加入二甲亚砜（DMSO），使终浓度为10mg FITC/1mL DMSO；将单抗溶液置于电磁搅拌器上，轻轻搅拌，以不起沫为准。按上述比例将FITC-DMSO溶液逐滴加入单抗溶液中，磁力搅拌器4℃避光搅拌24h；加完后，随时用试纸测定搅拌液的pH值，若低于9.0，则应以碳酸钠溶液调整。置4℃搅拌24h即可。用Sephadex G25柱过滤标记的荧光抗体，以去除游离荧光素。
4.2荧光抗体的最低检测线
在96孔微量培养板中加入依次加入浓度为40μg/mL、20μg/mL、10μg/mL、1.0μg/mL、0.10μg/mL、0.01μg/mL的重组人抑制素α链，每个浓度分别做8个孔，加入100μg/mL荧光抗体，100μL/孔，37℃孵育30min，PBS洗涤3次。最后用三蒸水洗2min，于酶标仪下记录，激发波长460nm，发射波长520nm。
结果显示：经荧光检测分析可知，如图1所示，本发明提供荧光标记的抗抑制素抗体能很好地实现对重组人抑制素α链的检测，且其在0.01-40μg/mL之间存在线性相关，可实现高灵敏地检测抑制素，能满足高通量，快速检测的要求，具有潜在推广应用价值。
在此有必要指出的是，以上实施例仅限于对本发明的技术方案做进一步的阐述和说明，并不是对本发明的技术方案的进一步的限制，本发明的方法仅为较佳的实施方案，并非用于限定本发明的保护范围。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (10)
1. 一种抗抑制素抗体，其特征在于，所述抗抑制素抗体重链可变区序列如SEQ IDNO.1所示，轻链可变区序列如SEQ ID NO.2所示。
2. 如权利要求1所述的抗抑制素抗体，其特征在于，所述抗抑制素抗体重链可变区包括CDR1、CDR2和CDR3，其序列分别对应于SEQ ID NO.3-5所示，所述抗抑制素抗体轻链可变区包括CDR4、CDR5和CDR6，其序列分别对应于SEQ ID NO.6-8。
3.一种荧光标记的抗抑制素抗体，其特征在于，采用荧光标记基团对权利要求1或2任一项所述的抗抑制素抗体进行标记。
4. 如权利要求3所述的荧光标记的抗抑制素抗体，其特征在于，所述荧光标记选自FITC、FAM、Rhodamine B、TAMRA、Cy3或Cy5。
5.如权利要求4所述的荧光标记的抗抑制素抗体，其特征在于，所述荧光标记为FITC。
6.一种非诊断目的抑制素直接免疫荧光检测方法，其特征在于，该方法包括采用权利要求3-5中任一项所述的荧光标记的抗抑制素抗体进行接触待检样本，在孵育结束后，在荧光显微镜下观察结果或酶标仪读取荧光值。
7.权利要求3-5中任一项所述的荧光标记的抗抑制素抗体在制备检测抑制素检测试剂盒中的应用。
8.权利要求1或2所述的抗抑制素抗体或权利要求3-5中任一项所述的荧光标记的抗抑制素抗体在制备用于刺激雌性哺乳动物卵泡发育、增加排卵数、增加受孕率或提高产仔量的药物中的应用。
9.如权利要求8所述的应用，其特征在于，所述雌性哺乳动物选择鼠、猪、牛、羊。
10.一种刺激雌性哺乳动物卵泡发育、增加排卵数、增加受孕率或提高产仔量的药物，其特征在于，所述药物包括权利要求1或2所述的抗抑制素抗体或权利要求3-5中任一项所述的荧光标记的抗抑制素抗体、和药学上可接受的辅料。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311211224.2A CN116948028B (zh) | 2023-09-20 | 2023-09-20 | 一种抗抑制素抗体及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311211224.2A CN116948028B (zh) | 2023-09-20 | 2023-09-20 | 一种抗抑制素抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116948028A true CN116948028A (zh) | 2023-10-27 |
| CN116948028B CN116948028B (zh) | 2023-11-28 |
Family
ID=88442839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311211224.2A Active CN116948028B (zh) | 2023-09-20 | 2023-09-20 | 一种抗抑制素抗体及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116948028B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102868A (en) * | 1990-01-08 | 1992-04-07 | Genentech, Inc. | Method for inhibiting follicular maturation |
| CN104012466A (zh) * | 2014-06-10 | 2014-09-03 | 江苏省农业科学院 | 促进牛发情和提高牛配种受胎率的方法 |
| CN105431455A (zh) * | 2013-02-01 | 2016-03-23 | 圣塔玛丽亚生物疗法公司 | 抗激活素a化合物对受试者的施用 |
| CN114075281A (zh) * | 2021-11-16 | 2022-02-22 | 福州迈新生物技术开发有限公司 | 抗Inhibin-α蛋白单克隆抗体、细胞系及其制备方法和应用 |
| CN114276449A (zh) * | 2021-12-31 | 2022-04-05 | 河南赛诺特生物技术有限公司 | 一种抗人抑制素α的单克隆抗体及其制备方法、免疫检测试剂、应用 |
| CN116262785A (zh) * | 2021-12-15 | 2023-06-16 | 宁波三生生物科技股份有限公司 | 抗抑制素抗体及其应用 |
-
2023
- 2023-09-20 CN CN202311211224.2A patent/CN116948028B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102868A (en) * | 1990-01-08 | 1992-04-07 | Genentech, Inc. | Method for inhibiting follicular maturation |
| CN105431455A (zh) * | 2013-02-01 | 2016-03-23 | 圣塔玛丽亚生物疗法公司 | 抗激活素a化合物对受试者的施用 |
| CN104012466A (zh) * | 2014-06-10 | 2014-09-03 | 江苏省农业科学院 | 促进牛发情和提高牛配种受胎率的方法 |
| CN114075281A (zh) * | 2021-11-16 | 2022-02-22 | 福州迈新生物技术开发有限公司 | 抗Inhibin-α蛋白单克隆抗体、细胞系及其制备方法和应用 |
| CN116262785A (zh) * | 2021-12-15 | 2023-06-16 | 宁波三生生物科技股份有限公司 | 抗抑制素抗体及其应用 |
| CN114276449A (zh) * | 2021-12-31 | 2022-04-05 | 河南赛诺特生物技术有限公司 | 一种抗人抑制素α的单克隆抗体及其制备方法、免疫检测试剂、应用 |
Non-Patent Citations (3)
| Title |
|---|
| AYUMI HASEGAWA等: "Use of anti-inhibin monoclonal antibody for increasing the litter size of mouse strains and its application to in vivo-genome editing technology", 《BIOLOGY OF REPRODUCTION》, pages 605 - 618 * |
| 丽娜・沙肯;巴合提・博代;杨华;解津刚;吾热力哈孜・哈孜汗;: "抑制素α基因诱导表达及其多克隆抗体的制备", 畜禽业, no. 04 * |
| 苗向阳;邵建军;朱瑞良;王建民;: "天然鼠源噬菌体抗体库的构建及抗羊抑制素基因工程单抗的筛选", 中国农业科学, no. 01, pages 299 - 303 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116948028B (zh) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9506933B2 (en) | Method of preparing antigen for acquiring anti-hydrophobic peptide antibody | |
| EP2105447A1 (en) | Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1 | |
| JPS60155133A (ja) | アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン | |
| Veselský et al. | Characterization of boar spermadhesins by monoclonal and polyclonal antibodies and their role in binding to oocytes | |
| KR101777254B1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
| CN116948028B (zh) | 一种抗抑制素抗体及其应用 | |
| US11906520B2 (en) | Composition and methods for detecting cancer | |
| DE3688204T2 (de) | Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens. | |
| US5514776A (en) | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface | |
| KR20090014979A (ko) | 신장암 진단 조성물 및 키트 | |
| CN110386973A (zh) | 具有多种功能的蛋白多肽及其医药用途 | |
| EP0582450A2 (en) | Anti-oxytocin receptor antibodies and methods for their production | |
| Banga et al. | Analysis of antigenic determinants of retinal S-antigen with monoclonal antibodies. | |
| Zhang et al. | Development and characterization of monoclonal antibodies against goose CD3ɛ extracellular domain and their application in detection of CD3+ T lymphocytes | |
| KR100493932B1 (ko) | 레지스틴에 대한 단클론 항체, 이의 제조 방법, 및 용도 | |
| EP0369425A1 (en) | Monoclonal antibody specifically recognizing N-glycolyl type GM2, hybridoma producing the antibody and method for preparing the hybridoma | |
| CN106589123A (zh) | 一种制备抗高糖基化人绒毛膜促性腺激素抗体的方法 | |
| JP2614822B2 (ja) | 抗体産生ハイブリドーマの作製方法 | |
| WO2024140145A1 (zh) | 一种靶向免疫细胞的抗体或其功能性片段及其应用 | |
| GEE et al. | Dissection of renal brush-border membranes with monoclonal antibodies | |
| Hayat | Antigens and antibodies | |
| CN112062847A (zh) | 一种inhb抗体及其应用 | |
| Bashir et al. | Generation of a monoclonal antibody to P-glycoprotein peptides using tuberculin-PPD as a carrier | |
| JP3522877B2 (ja) | 抗チロシナーゼモノクローナル抗体Ｆ（ａｂ’）２フラグメント | |
| Li | Characterization of Monoclonal Mouse IgG Antibodies to Cod IgM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |